https://www.openbell.ai/ 2026-10-08T11:42:47.024Z hourly 1.0 https://www.openbell.ai/support 2026-10-08T11:42:47.024Z monthly 0.7 https://www.openbell.ai/privacy 2026-10-08T11:42:47.024Z monthly 0.5 https://www.openbell.ai/terms 2026-10-08T11:42:47.024Z monthly 0.5 https://www.openbell.ai/feed.json 2026-10-08T11:42:47.024Z hourly 0.8 https://www.openbell.ai/news/SOXX:1791459752309 2026-10-08T11:42:32.309Z daily 0.9 https://cdn.brandfetch.io/SOXX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jim Cramer Says Oil Surge, Higher Rates Are ‘Convenient Excuses’ To Sell Semis as QQQ, SOXX Drop and Investors Question Data Center Spending Jim Cramer highlighted a recent technology sell-off, particularly in the Invesco QQQ Trust (QQQ) and iShares Semiconductor ETF (SOXX), attributing it to rising oil prices and interest rates rather than inherent weaknesses in the semiconductor sector. On October 7, QQQ closed at $757.73, down 0.25%, and fell to $752.15 in pre-market trading, while SOXX dropped 1.12% to $582.82 and further declined to $570.94 pre-market. Cramer suggested that investors are incorrectly linking macroeconomic pressures to a peak in data center spending, leading to the sell-off in semiconductor stocks. https://www.openbell.ai/news/PSNY:1791459703308 2026-10-08T11:41:43.308Z daily 0.9 https://cdn.brandfetch.io/PSNY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Polestar CEO Says Company Has Nearly Sold All Remaining 2026 Model-Year Cars In U.S.; Sees Very Good UK Demand For Polestar 5 Polestar's CEO announced that the company has nearly sold all of its remaining 2026 model-year cars in the U.S. Additionally, there is strong demand for the Polestar 5 in the UK market. The company's stock is traded under the ticker PSNY. https://www.openbell.ai/news/DVN:1791459608914 2026-10-08T11:40:08.914Z daily 0.9 https://cdn.brandfetch.io/DVN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Devon Energy shares are trading higher after the company announced it will sell its Eagle Ford assets to Crescent Energy. openbell Financial News https://www.openbell.ai/news/PCRX:1791459600898 2026-10-08T11:40:00.898Z daily 0.9 https://cdn.brandfetch.io/PCRX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trading Halt: Halted at 7:40:00 a.m. ET - Trading Halt: Halt News Pending openbell Financial News https://www.openbell.ai/news/SPY:1791459528500 2026-10-08T11:38:48.500Z daily 0.9 https://cdn.brandfetch.io/SPY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Reported October 7, 'Military ordered to be ready for possible Iran strikes as Trump weighs timing' - Axios On October 7, it was reported that the U.S. military has been ordered to prepare for potential strikes against Iran as former President Trump considers the timing of such actions. This development comes amid ongoing tensions related to the Israel-Iran conflict and could have implications for U.S. foreign policy and military strategy. The situation may also influence market dynamics, particularly for defense-related stocks. https://www.openbell.ai/news/PEP:1791459520943 2026-10-08T11:38:40.943Z daily 0.9 https://cdn.brandfetch.io/PEP/w/400/h/400?c=1idopYfmtR7ZKg8QMud PepsiCo shares are trading higher after the company reported better-than-expected Q3 financial results and narrowed its FY26 sales guidance above estimates. openbell Financial News https://www.openbell.ai/news/RMBS:1791459343528 2026-10-08T11:35:43.528Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/08/CNBC-Mad-Money-Host-Jim-Cramer.jpg?width=250&height=187 Jim Cramer Doesn’t Like This Health Care Stock, Sees No Reason To Buy Rambus Jim Cramer expressed skepticism about Rambus Inc. (NASDAQ: RMBS), stating he sees no reason to buy the stock due to a lack of catalysts, as it has not intrigued him. Rambus is scheduled to hold a conference call on October 26 to discuss its third-quarter results. Recently, Rambus shares fell by 2.3% to close at $111.48. https://www.openbell.ai/news/U:1791459303655 2026-10-08T11:35:03.655Z daily 0.9 https://cdn.brandfetch.io/U/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Upgrades Unity Software to Outperform, Announces $54 Price Target Raymond James analyst Andrew Marok has upgraded Unity Software (NYSE: U) from Market Perform to Outperform, setting a price target of $54 for the stock. This upgrade reflects a positive outlook on the company's performance. https://www.openbell.ai/news/VABK:1791459258222 2026-10-08T11:34:18.222Z daily 0.9 https://cdn.brandfetch.io/VABK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Virginia National Bankshares Announces $18.7M Stock Buyback openbell Financial News https://www.openbell.ai/news/TGB:1791459243011 2026-10-08T11:34:03.011Z daily 0.9 https://cdn.brandfetch.io/TGB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Trekor Metals Produces 41M Pounds Of Copper In Q3 From Its Gibraltar Mine, Florence Copper Production Site Trekor Metals Limited reported third quarter production of 41 million pounds of copper from its Gibraltar mine and Florence Copper production site. The Gibraltar mine alone produced 34 million pounds of copper and 380 thousand pounds of molybdenum, contributing to a 12% increase in quarterly production. Additionally, copper sales from Gibraltar reached 31 million pounds during this period. https://www.openbell.ai/news/ARGX:1791459236309 2026-10-08T11:33:56.309Z daily 0.9 https://cdn.brandfetch.io/ARGX/w/400/h/400?c=1idopYfmtR7ZKg8QMud argenx shares are trading lower after the company announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous after the Independent Data Monitoring Committee concluded it is unable to meet its primary endpoint. openbell Financial News https://www.openbell.ai/news/GNRC:1791459218471 2026-10-08T11:33:38.471Z daily 0.9 https://cdn.brandfetch.io/GNRC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Piper Sandler Initiates Coverage On Generac Holdings with Overweight Rating, Announces Price Target of $303 Piper Sandler analyst Dimple Gosai has initiated coverage on Generac Holdings (NYSE: GNRC) with an Overweight rating. The firm has set a price target of $303 for the company's stock. https://www.openbell.ai/news/GAU:1791459203655 2026-10-08T11:33:23.655Z daily 0.9 https://cdn.brandfetch.io/GAU/w/400/h/400?c=1idopYfmtR7ZKg8QMud Galiano Gold Says Ghana Extends Abirem And Miradani Mining Leases At Asanko Gold Mine Through 2041 And 2043 openbell Financial News https://www.openbell.ai/news/CMND:1791459191345 2026-10-08T11:33:11.345Z daily 0.9 https://cdn.brandfetch.io/CMND/w/400/h/400?c=1idopYfmtR7ZKg8QMud Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia Clearmind Medicine Inc. (Nasdaq: CMND) has published a patent application in Japan for novel compositions and methods aimed at treating dyskinesia, a neurological movement disorder. The application focuses on the use of 3-Methylmethcathinone (3-MMC) to prevent or reduce symptoms of dyskinesia, and includes claims for combinations of 3-MMC with Palmitoylethanolamide (PEA), known for its anti-inflammatory and neuroprotective properties. https://www.openbell.ai/news/HYPR:1791459177113 2026-10-08T11:32:57.113Z daily 0.9 https://cdn.brandfetch.io/HYPR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hyperfine Reports Preliminary Q3 Revenue Of ~$6M, Up 53% Sequentially; Net Cash Burn ~$5.6M, Down 29% openbell Financial News https://www.openbell.ai/news/SWVL:1791459166348 2026-10-08T11:32:46.348Z daily 0.9 https://cdn.brandfetch.io/SWVL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Swvl Hldgs H1 Sales $16.200M Up From $10.190M YoY Swvl Hldgs reported sales of $16.200 million for the first half of the year, marking a 58.98% increase from $10.190 million in the same period last year. The company's strong performance reflects significant growth in revenue year-over-year. https://www.openbell.ai/news/GPN:1791459134464 2026-10-08T11:32:14.464Z daily 0.9 https://cdn.brandfetch.io/GPN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oppenheimer Upgrades Global Payments to Outperform, Announces $115 Price Target Oppenheimer analyst Rayna Kumar has upgraded Global Payments (NYSE: GPN) from 'Perform' to 'Outperform' and set a price target of $115 for the stock. This upgrade indicates a positive outlook for the company's performance in the market. https://www.openbell.ai/news/AGEN:1791459082041 2026-10-08T11:31:22.041Z daily 0.9 https://cdn.brandfetch.io/AGEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer Agenus Inc. has received marketing authorization from the Ministry of Health of Armenia for its drugs Botvymo (botensilimab) and Evamplix (balstilimab) to treat adult patients with microsatellite stable metastatic colorectal cancer. This marks the first marketing authorization for both medicines globally. The approvals are anticipated to benefit both local patients and those traveling to Armenia for treatment. https://www.openbell.ai/news/SPCX:1791459017722 2026-10-08T11:30:17.722Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/08/Elon-Musk--founder--CEO--and-chief-engin.jpg?width=250&height=187 SPCX CEO Elon Musk Has a Warning for Anyone Betting on AI: The Compute Crunch Is Coming — ‘People Have No Idea’ Elon Musk, CEO of Space Exploration Technologies Corp. (NASDAQ: SPCX), has echoed Box Inc. CEO Aaron Levie's warning about the impending demand for compute power due to the rise of autonomous AI agents. Musk highlighted that the infrastructure needed for AI will be immense, with Wall Street estimating that agentic AI could add between $32.5 billion to $60 billion to the data-center CPU market by 2030. Additionally, the International Energy Agency predicts that global data-center electricity consumption will more than double by 2030, driven largely by AI advancements. https://www.openbell.ai/news/CRGY:1791458664491 2026-10-08T11:24:24.491Z daily 0.9 https://cdn.brandfetch.io/CRGY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Crescent Energy Company Commences $1B Class A Common Stock Offering Crescent Energy Company (NYSE: CRGY) has announced a public offering of $1 billion of its Class A common stock, following an effective shelf registration statement filed with the SEC. The company plans to utilize the net proceeds from this offering for unspecified purposes. This move marks a significant financial maneuver for Crescent Energy as it seeks to raise capital. https://www.openbell.ai/news/CGEM:1791458587561 2026-10-08T11:23:07.561Z daily 0.9 https://cdn.brandfetch.io/CGEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cullinan Therapeutics Announces First Patient Dosed In Pivotal Phase 2 Study Of CLN-049 In Relapsed AML; Expects Phase 1 Update In December openbell Financial News https://www.openbell.ai/news/ACON:1791458516363 2026-10-08T11:21:56.363Z daily 0.9 https://cdn.brandfetch.io/ACON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Aclarion Says Enrollment Insufficient For Q4 2026 Initial Readout Of CLARITY Trial; Will Update Timing By Year-End, Says Overall Trial Duration Unchanged openbell Financial News https://www.openbell.ai/news/BMY:1791458496046 2026-10-08T11:21:36.046Z daily 0.9 https://cdn.brandfetch.io/BMY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bristol Myers Squibb Says Zenbexus Combo Shows 51% Lower Risk Of Myeloma Progression Or Death vs. Standard Of Care In Phase 3 openbell Financial News https://www.openbell.ai/news/WBX:1791458445153 2026-10-08T11:20:45.153Z daily 0.9 https://cdn.brandfetch.io/WBX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wallbox Announces European Launch Of New Pulsar Max Home EV Charger, Expected To Be Available From November openbell Financial News https://www.openbell.ai/news/NTRB:1791458402508 2026-10-08T11:20:02.508Z daily 0.9 https://cdn.brandfetch.io/NTRB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nutriband Files U.S. Patent Application To Increase Protection For Its AVERSA Abuse Deterrent Transdermal Technology Nutriband has filed a U.S. patent application aimed at enhancing the protection of its AVERSA abuse deterrent transdermal technology. If granted, this patent could extend protection for AVERSA-based products, such as AVERSA FENTANYL, until 2046. The technology is designed to incorporate aversive agents into transdermal patches to mitigate the abuse of drugs, particularly opioids and stimulants, while ensuring accessibility for patients in need. https://www.openbell.ai/news/EDIT:1791458305152 2026-10-08T11:18:25.152Z daily 0.9 https://cdn.brandfetch.io/EDIT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia Editas Medicine has received approval to initiate its Phase 1/2 Strive clinical trial of EDIT-401 for patients with heterozygous familial hypercholesterolemia in Australia, having completed the necessary regulatory processes. The trial is also under review in New Zealand, which could allow patient enrollment in both countries. EDIT-401 is an experimental gene editing treatment that has shown a mean reduction of approximately 90% in LDL-C levels in preclinical studies, with further data set to be presented at the AHA Scientific Sessions in November 2026. https://www.openbell.ai/news/GILT:1791458198201 2026-10-08T11:16:38.201Z daily 0.9 https://cdn.brandfetch.io/GILT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gilat Satellite Networks' Datapath Receives Pentagon Orders Totaling $8M+ Gilat Satellite Networks' subsidiary, Gilat DataPath, has received orders from the Pentagon totaling over $8 million, with deliveries expected over the next 12 months. These orders enhance Gilat Defense's role in U.S. defense programs and reflect a sustained demand for its SATCOM expertise and operational support capabilities. The contracts will support deployed U.S. military communications systems by integrating field services with SATCOM upgrades to meet evolving operational needs. https://www.openbell.ai/news/IONQ:1791458189786 2026-10-08T11:16:29.786Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/08/Munich--Bavaria--Germany---March-31-2023.jpg?width=250&height=187 What's Going On With IonQ Stock Today? IonQ, Inc. has advanced to the final stage of DARPA's Quantum Benchmarking Initiative, which adds government validation to its technology and supports its push for larger commercial deployments. The stock rose nearly 2% in premarket trading, despite a nearly 10% decline throughout 2026 due to expanding net losses. IonQ signed a $300 million agreement with DARPA for independent testing of its Superion systems through 2029, and analysts from BofA Securities initiated coverage with a Buy rating and a $60 price forecast, citing IonQ's strong revenue position in the quantum computing sector. https://www.openbell.ai/news/ACB:1791458067180 2026-10-08T11:14:27.180Z daily 0.9 https://cdn.brandfetch.io/ACB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Aurora Cannabis Completes Major Expansion Of Its Facility In Leuna, Germany Aurora Cannabis has completed a significant expansion of its facility in Leuna, Germany, involving a multi-million-dollar investment that more than doubles the expected annual flower output. The enhanced facility utilizes Aurora's proven cultivation practices and proprietary genetics to ensure consistent, high-quality production. This expansion also increases the company's EU-GMP manufacturing capacity, enabling Aurora to meet the growing demand for compliant, high-quality products across European markets. https://www.openbell.ai/news/APLD:1791457931332 2026-10-08T11:12:11.332Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/08/Denver--Colorado---June-12-2025-Applied-.jpg?width=250&height=187 APLD CEO Sees 'Scarcity Value' Driving AI Data Center Lease Rates by Over 15% on 250MW Expansion Applied Digital Corp. (NASDAQ: APLD) anticipates securing 250 megawatts (MW) of AI data center leases by year-end, with rates expected to exceed a 15% increase over previous contracts due to 'scarcity value' in a constrained power market. In its fiscal first quarter, the company reported revenue of $341.9 million, a 322% year-over-year increase, despite an adjusted loss of $0.01 per share. The company is also expanding its operational capacity, targeting a growth to 3.5 to 4 gigawatts by the end of 2030, supported by new power purchase agreements. https://www.openbell.ai/news/GKOS:1791457904352 2026-10-08T11:11:44.352Z daily 0.9 https://cdn.brandfetch.io/GKOS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Glaukos Enters Exclusive License Agreement With RevOpsis Therapeutics To Develop And Commercialize RO-104, A Novel Tri-Specific Biologic Glaukos has entered an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a novel tri-specific biologic aimed at treating conditions such as neovascular age-related macular degeneration and diabetic macula edema. The agreement also provides Glaukos with exclusive rights to RevOpsis' RevMod™ platform for the discovery and development of up to four additional retinal biologic candidates. RO-104 is engineered to block key angiogenic pathways and has shown superior preclinical efficacy compared to existing anti-VEGF therapies. https://www.openbell.ai/news/GOGO:1791457777916 2026-10-08T11:09:37.916Z daily 0.9 https://cdn.brandfetch.io/GOGO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Gogo Signs $15M+ Communications Lease To Provide Geostationary Satellite Connectivity To A Government Customer Gogo has signed a communications lease worth over $15 million to provide geostationary satellite connectivity to a government customer, ensuring reliable communication for aircraft carrying government leaders. This solution offers global connectivity, particularly in regions where low Earth orbit satellite services are limited. The customer's choice highlights their emphasis on cybersecurity and data privacy, aligning with Gogo's commitment to minimizing data retention and enhancing network security. https://www.openbell.ai/news/SPWR:1791457658861 2026-10-08T11:07:38.861Z daily 0.9 https://cdn.brandfetch.io/SPWR/w/400/h/400?c=1idopYfmtR7ZKg8QMud SunPower Unveils New Monolith II Next-Generation Premium High-Wattage Panel SunPower has launched the Monolith II, a next-generation premium solar panel that produces 522 watts, surpassing its previous 333-watt record set in 2009. This panel is part of a Joint Development Agreement with REC and utilizes advanced N-Type Heterojunction (HJT) cell technology, promising improved energy output and a 25-year warranty. The Monolith II is designed to maximize annual energy production by using a bifacial design, allowing light to illuminate the cells from both sides. https://www.openbell.ai/news/APO:1791457374857 2026-10-08T11:02:54.857Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/08/The-Us-Housing-Market-Continues-To-Be-A-.jpg?width=250&height=187 US Housing Affordability Nears Worst Level Since Financial Crisis as J.P. Morgan Says Market Is Effectively ‘Frozen’ U.S. housing affordability is nearing its worst level since the financial crisis, with the cost for renters to purchase a median-priced home now consuming approximately 50% of median income. J.P. Morgan analysts noted that about 75% of borrowers have mortgage rates below 5%, contributing to a market that is effectively 'frozen' due to high mortgage rates, a shortage of 1.2 million homes, and weak income growth. Mortgage purchase applications have dropped to their lowest level since 1995, down 50% from pandemic peaks, while the typical monthly mortgage payment is around $2,800, or 38% of a typical household's gross income. https://www.openbell.ai/news/CNTB:1791456966038 2026-10-08T10:56:06.038Z daily 0.9 https://cdn.brandfetch.io/CNTB/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target HC Wainwright & Co. analyst Brandon Folkes has reiterated a 'Buy' rating on Connect Biopharma Holdings (NASDAQ: CNTB) and maintained a price target of $7 for the stock. No additional financial figures or strategic changes were mentioned in the article. https://www.openbell.ai/news/TOYO:1791456576719 2026-10-08T10:49:36.719Z daily 0.9 https://cdn.brandfetch.io/TOYO/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Toyo Co, Maintains $18 Price Target HC Wainwright & Co. analyst Amit Dayal has reiterated a Buy rating on Toyo Co (NASDAQ: TOYO) and maintained a price target of $18 for the stock. https://www.openbell.ai/news/NVDA:1791456418111 2026-10-08T10:46:58.111Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Nvidia-Backed IPO’s Cratering Demand Sends Warning on AI Funding' - Bloomberg Recent IPOs backed by Nvidia are experiencing a significant decline in demand, raising concerns about the future of funding in the AI sector. This trend could indicate a broader market shift affecting investments in artificial intelligence technologies. The situation highlights potential challenges for companies looking to raise capital in the current economic climate. https://www.openbell.ai/news/F:1791456408614 2026-10-08T10:46:48.614Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/08/Jim-Farley-Says-5-Years-At-Ford-Were-Ful.jpg?width=250&height=187 Jim Farley Says Ford's Next-Gen EVs Will Check Themselves for Assembly Defects: 'The Vehicle Diagnoses Itself' Ford Motor Co. CEO Jim Farley announced that the company's upcoming Universal EV Platform will enable vehicles to self-diagnose assembly defects during production, aiming to enhance quality control after experiencing 78 recalls this year. The system will allow vehicles to conduct internal checks shortly after receiving power, while still utilizing traditional inspection methods. Ford is set to launch its all-electric Fathom pickup, the first vehicle on this platform, with a starting MSRP of $28,350 and preorders beginning in early 2027. https://www.openbell.ai/news/HELE:1791456367115 2026-10-08T10:46:07.115Z daily 0.9 https://cdn.brandfetch.io/HELE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Helen Of Troy Raises FY2027 GAAP EPS Guidance from $3.57-$4.18 to $3.63-$4.26 vs $3.77 Est Helen Of Troy (NASDAQ: HELE) has raised its FY2027 GAAP EPS guidance from a range of $3.57-$4.18 to $3.63-$4.26, surpassing the analyst estimate of $3.77. This adjustment reflects a positive outlook for the company's earnings in the upcoming fiscal year. https://www.openbell.ai/news/HELE:1791456337757 2026-10-08T10:45:37.757Z daily 0.9 https://cdn.brandfetch.io/HELE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Helen Of Troy Raises FY2027 Adj EPS Guidance from $3.25-$3.75 to $3.60-$4.15 vs $3.55 Est; Narrows FY2027 Sales Guidance from $1.759B-$1.831B to $1.768B-$1.822B vs $1.808B Est Helen Of Troy (NASDAQ: HELE) has raised its FY2027 adjusted EPS guidance from a range of $3.25-$3.75 to $3.60-$4.15, surpassing the analyst estimate of $3.55. Additionally, the company has narrowed its FY2027 sales outlook from $1.759 billion-$1.831 billion to $1.768 billion-$1.822 billion, compared to an estimate of $1.808 billion. https://www.openbell.ai/news/LLY:1791456236737 2026-10-08T10:43:56.737Z daily 0.9 https://cdn.brandfetch.io/LLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440 Cantor Fitzgerald analyst Carter Gould has maintained an Overweight rating on Eli Lilly (NYSE: LLY) and raised the price target from $1410 to $1440. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/GILD:1791456172400 2026-10-08T10:42:52.400Z daily 0.9 https://cdn.brandfetch.io/GILD/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target Cantor Fitzgerald analyst Carter Gould has reiterated an 'Overweight' rating on Gilead Sciences (NASDAQ: GILD) and maintained a price target of $155 for the stock. This endorsement suggests confidence in Gilead's future performance in the market. https://www.openbell.ai/news/HNRG:1791456166625 2026-10-08T10:42:46.625Z daily 0.9 https://cdn.brandfetch.io/HNRG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Hallador Energy Enters Six-Year, $700M Capacity And Energy Agreements With A MISO Zone 6 Utility Covering Deliveries From The Merom Generating Station From June 1, 2029, Through May 31, 2035; Revenue Jumps from $46/MWh For 2026 To $75/MWh For 2031-2035 Hallador Energy has entered into six-year capacity and energy agreements worth $700 million with a MISO Zone 6 utility, covering deliveries from the Merom Generating Station from June 1, 2029, to May 31, 2035. The capacity agreement, priced at the highest level to date, will generate approximately $271 million in capacity revenue, while the energy agreement is expected to yield around $422 million. These agreements increase Hallador's total forward sales book to $3 billion and secure approximately 95% of Merom's accredited capacity through 2035. Additionally, the company is advancing its Turtle Creek natural gas project, which would expand its generating capacity by over 40%. https://www.openbell.ai/news/NVA:1791455876432 2026-10-08T10:37:56.432Z daily 0.9 https://cdn.brandfetch.io/NVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nova Minerals Announces That Equipment For Its Planned Antimony Processing And Refinery Operation Arrived At Port Mackenzie On October 6 Nova Minerals has announced the arrival of key equipment for its planned antimony processing and refinery operation at Port Mackenzie on October 6, enabling construction to begin pending final permits. This milestone supports the company's initiative to create a vertically integrated U.S. domestic antimony supply chain in Alaska, backed by a $43.4 million award from the U.S. Department of War. Additionally, the 2026 field program at the Estelle Critical Minerals and Gold Project has been completed, with initial assay results expected soon. https://www.openbell.ai/news/ABBV:1791455809599 2026-10-08T10:36:49.599Z daily 0.9 https://cdn.brandfetch.io/ABBV/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290 Cantor Fitzgerald analyst Carter Gould has maintained an Overweight rating on AbbVie (NYSE: ABBV) and raised the price target from $285 to $290. This adjustment reflects a positive outlook on the company's performance. https://www.openbell.ai/news/SPTX:1791455719180 2026-10-08T10:35:19.180Z daily 0.9 https://cdn.brandfetch.io/SPTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Seaport Therapeutics (NASDAQ: SPTX) and maintained a price target of $50 for the stock. https://www.openbell.ai/news/RDY:1791455631435 2026-10-08T10:33:51.435Z daily 0.9 https://cdn.brandfetch.io/RDY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Dr Reddy's Says FDA Completed Pre-Approval Inspection At The FTO-11 Manufacturing Facility In Pydibhimavaram Dr Reddy's Laboratories announced that the FDA has completed a pre-approval inspection at its FTO-11 manufacturing facility located in Pydibhimavaram. This inspection is a crucial step in the regulatory process for the company's products. The outcome of the inspection may impact the company's ability to launch new pharmaceutical products in the market. https://www.openbell.ai/news/AVGO:1791455559519 2026-10-08T10:32:39.519Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/10/08/Konskie--Poland---January-11--2024-Broad.jpg?width=250&height=187 Broadcom Eyes Over $50 Billion to Fund OpenAI’s Custom AI Chips as Oracle Also Pursues Major Chip Financing: Report Broadcom Inc. is seeking over $50 billion in financing to develop custom AI chips for OpenAI, with discussions involving Apollo Global Management and Blackstone. The funding aims to support significant chip capacity for AI data centers, with expectations for the deal to close by year-end. Separately, Oracle is also pursuing substantial financing for a large-scale chip purchase, negotiating with Apollo and Goldman Sachs. https://www.openbell.ai/news/CRBU:1791455355481 2026-10-08T10:29:15.481Z daily 0.9 https://cdn.brandfetch.io/CRBU/w/400/h/400?c=1idopYfmtR7ZKg8QMud HC Wainwright & Co. Downgrades Caribou Biosciences to Neutral HC Wainwright & Co. analyst Robert Burns has downgraded Caribou Biosciences (NASDAQ: CRBU) from a 'Buy' rating to 'Neutral'. This change reflects a shift in the firm's outlook on the company's performance. https://www.openbell.ai/news/NOMD:1791455049593 2026-10-08T10:24:09.593Z daily 0.9 https://cdn.brandfetch.io/NOMD/w/400/h/400?c=1idopYfmtR7ZKg8QMud BTIG Reiterates Buy on Nomad Foods, Maintains $15 Price Target BTIG analyst Peter Saleh has reiterated a Buy rating on Nomad Foods (NYSE: NOMD) and maintained a price target of $15. This endorsement reflects confidence in the company's performance and market position.